Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD

BioCentury
|
July 17, 2023
X min read
BioCentury
|
July 17, 2023
Share on Social
share on Twitter or X
share on Linkedin
share onFacebook
share on Bluesky

More like this

Media

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Read Now
Press

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Read Now
Media

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2026

Read Now
Press

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2026

Read Now
Media

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

July 27, 2026

Barron's

Read Now
Press

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

July 27, 2026

Barron's

Read Now
See More